Incidence of progression to accelerated and/or blast phase in the major frontline TKI studies in chronic phase CML
| Clinical trial (follow-up in years) . | Frontline TKI (dose) . | |||
|---|---|---|---|---|
| Imatinib . | Nilotinib . | Dasatinib . | Bosutinib . | |
| IRIS42 (10 years) | 7% (400 mg) | |||
| TOPS43 (42 months) | 4.5% (400 mg)/2.5% (800 mg) | |||
| CML-IV44 (10 years) | 6% (400 mg)/5% (800 mg) | |||
| TIDEL-II45 (40 months) | 3.5% (600 mg) | |||
| ENESTnd46 (10 years) | 8.5% (400 mg) | 4% (300 mg BD)/2% (400 mg BD) | ||
| ENESTfirst (24 months) | 0.6% (300 mg BD) | |||
| DASISION47 (5 years) | 7% (400 mg) | 5% (100 mg) | ||
| BFORE48 (5 years) | 3% (400 mg) | 2% (400 mg) | ||
| Clinical trial (follow-up in years) . | Frontline TKI (dose) . | |||
|---|---|---|---|---|
| Imatinib . | Nilotinib . | Dasatinib . | Bosutinib . | |
| IRIS42 (10 years) | 7% (400 mg) | |||
| TOPS43 (42 months) | 4.5% (400 mg)/2.5% (800 mg) | |||
| CML-IV44 (10 years) | 6% (400 mg)/5% (800 mg) | |||
| TIDEL-II45 (40 months) | 3.5% (600 mg) | |||
| ENESTnd46 (10 years) | 8.5% (400 mg) | 4% (300 mg BD)/2% (400 mg BD) | ||
| ENESTfirst (24 months) | 0.6% (300 mg BD) | |||
| DASISION47 (5 years) | 7% (400 mg) | 5% (100 mg) | ||
| BFORE48 (5 years) | 3% (400 mg) | 2% (400 mg) | ||
BD, twice daily.